Stephen Larsen, OD
Optometrist · Harlingen, TXNPI 1720148604
Payments from drug & device makers
Across 210 payments — averaging $39.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$960
- AbbVie$763
- Alcon$735
- Oyster Point Pharma, Inc.$504
- Coopervision Inc.$495
- Novartis$471
- plus $4K from 22 others
What the payments were for
- Food & beverage$8,336100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 31 | $960 |
| AbbVie(2 entities) | 21 | $763 |
| Alcon | 20 | $735 |
| Oyster Point Pharma, Inc. | 24 | $504 |
| Coopervision Inc. | 12 | $495 |
| Novartis | 33 | $471 |
| Astellas Pharma US Inc | 4 | $415 |
| Tarsus Pharmaceuticals, Inc. | 6 | $401 |
| Genentech USA, Inc. | 4 | $388 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $287 |
| Biotissue Holdings Inc. | 4 | $268 |
| Eyevance Pharmaceuticals LLC | 3 | $261 |
| Glaukos Corporation | 2 | $252 |
| Regeneron Healthcare Solutions, Inc. | 2 | $251 |
| Aerie Pharmaceuticals, Inc. | 8 | $229 |
| Dompe US, Inc. | 2 | $220 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $183 |
| Rxsight Inc | 2 | $177 |
| Merz Pharmaceuticals, LLC | 1 | $164 |
| Mallinckrodt Hospital Products Inc. | 2 | $156 |
| LKC Technologies, Inc. | 1 | $137 |
| Tearlab Corp | 3 | $132 |
| Sight Sciences, Inc. | 1 | $128 |
| Kala Pharmaceuticals, Inc. | 1 | $123 |
| Apellis Pharmaceuticals, Inc. | 1 | $103 |
| Shire North American Group Inc | 3 | $63 |
| Sun Pharmaceutical Industries Inc. | 3 | $55 |
| Johnson & Johnson Vision Care, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$371
- DURYSTA$368
- MIEBO$348
- XDEMVY$347
- XIIDRA$240
- XEOMIN$164
- TRYPTYR$150
- CE-marked KXLA system$134
- Zerviate$128
- OMNI(R) SURGICAL SYSTEM (US)$128
- ACTHAR$128
- EYLEA$126
- Multiple Brands Contact Lens$125
- EYLEA HD$125
- TYRVAYA$125
- EYSUVIS$123
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$122
- Rocklatan$122
- Rhopressa$122
- Oxervate$121
How this compares
$8,336 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 62 | $67,474 |
| RestasisCyclosporine | 34 | $40,486 |
| RocklatanNetarsudil Mesylat/Latanoprost | 59 | $27,990 |
| MieboPerfluorohexyloctane/Pf | 31 | $25,545 |
| LumiganBimatoprost | 22 | $13,826 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 48 | $12,657 |
| TyrvayaVarenicline Tartrate | 14 | $9,276 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 24 | $6,279 |
| ProlensaBromfenac Sodium | 12 | $5,433 |
| Latanoprost | 411 | $4,472 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 180 | $2,502 |
| Travoprost | 14 | $1,653 |
| Doxycycline Hyclate | 21 | $1,622 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 44 | $649 |
| Timolol Maleate | 37 | $349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $960 | $93,01993 claims |
| AbbVieRestasis, Lumigan | $763 | $54,31156 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $229 | $27,99059 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $504 | $9,27614 claims |
| AlconSimbrinza | $735 | $6,27924 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $183 | $5,43312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Harlingen
- Lauro GuerreroHarlingen$133K
- Tiffany HuynhHouston$3.2M
- Bridgitte LeeHouston$3M
- Bryan FrazierTyler$1.4M
- Derek CunninghamAustin$940K
- Wendy ChungKaty$900K
- Phillip BrunsonHouston$766K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$568K
- Mina VanrachackSan Antonio$553K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.